Metribolone , 98% , 965-93-5
Synonym(s):
(17b)-17-Hydroxy-17-methyl-Estra-4,9,11-trien-3-one;Methyltrienolone;Metribolone;NSC 92858;RU 1881
CAS NO.:965-93-5
Empirical Formula: C19H24O2
Molecular Weight: 284.39
MDL number: MFCD00199021
EINECS: 663-842-3
Pack Size | Price | Stock | Quantity |
100mg | RMB493.60 | In Stock |
|
500mg | RMB1836.00 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 170° |
alpha | D20 -58.7° (c = 0.5 in ethanol) |
Boiling point: | 485.9±45.0 °C(Predicted) |
Density | 1.17±0.1 g/cm3(Predicted) |
storage temp. | 2-8°C |
solubility | DMSO: ≥10mg/mL |
pka | 14.79±0.40(Predicted) |
form | powder |
color | light yellow to yellow |
optical activity | [α]/D -48 to -68° |
InChI | InChI=1/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/s3 |
InChIKey | CCCIJQPRIXGQOE-XWSJACJDSA-N |
SMILES | [C@@]12([H])CC[C@@](O)(C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H] |&1:0,4,7,21,r| |
CAS DataBase Reference | 965-93-5(CAS DataBase Reference) |
Description and Uses
Methyltrienolone, also called metribolone, is an orally active anabolic-androgen steroid being a 17α-alkylated nandrolone (19-nortestosterone) derivative. It is not sold as a prescription drug or a dietary supplement due to its strong androgenic side effects and liver toxicity. However, it is often used as the reference point for in vitro biological activity for biochemical studies. It can bind strongly to the androgen receptor and can be used as an affinity label of the androgen receptor in the prostate and prostatic tumors.
Methyltrienolone is a synthetic derivative of testosterone that is used in the medical field as an androgen and anabolic agent. It has been used to treat breast cancer, prostate cancer, and other cancers that are sensitive to hormones.
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H319 |
Precautionary statements | P305+P351+P338 |
WGK Germany | 3 |
DEA Controlled Substances | CSCN: 4000 CSA SCH: Schedule III NARC: No |